Testosterone, sex hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk: observational and Mendelian randomization analyses

What Was Tested

The paper reports a study of IGF-1 LR3 in the context of endometriosis, published as an observational study.

Dysregulation of endocrine pathways related to steroid and growth hormones may modify endometrial cancer risk; however, prospective data on testosterone, sex hormone-binding globulin (SHBG) and insulin-like growth factor (IGF)-1 are limited.

To elucidate the role of these hormones in endometrial cancer risk the researchers conducted complementary observational and Mendelian randomization (MR) analyses.

Who Took Part

The abstract describes 159,702 women taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

What Was Measured

Dysregulation of endocrine pathways related to steroid and growth hormones may modify endometrial cancer risk; however, prospective data on testosterone, sex hormone-binding globulin (SHBG) and insulin-like growth factor (IGF)-1 are limited.

PubMed files the paper under topics including Biological Specimen Banks, Endometrial Neoplasms, Genetic Association Studies, Genetic Variation, Insulin-Like Growth Factor I, Mendelian Randomization Analysis and Postmenopause.

What This Means in Plain Language

This is an observational study of IGF-1 LR3 in 159,702 women in people with endometriosis.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (British journal of cancer), a journal based in England.

More context: the IGF-1 LR3 compound page, Endometriosis research.